Menu Close

Articles on AstraZeneca

Displaying 1 - 20 of 79 articles

Vanquishing the enemy? People stand in a quick moving line up at a mass vaccination centre during the COVID-19 pandemic in Mississauga, Ont., on May 10, 2021. THE CANADIAN PRESS/Nathan Denette

Confusing AstraZeneca warfare messaging: Destroy the COVID-19 enemy fast, but wait

Public officials are telling us simultaneously to move swiftly on vaccination and also to make thoughtful, reasoned choices about which vaccine we get. These messages are confusing and frustrating.
At the end of 2020, India applied to the WTO for a temporary suspension of intellectual property rights related to Covid-19. Sanjay Kanojia/AFP

Intellectual property and Covid-19: how can we accelerate vaccination globally?

Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
The AstraZeneca vaccine was 70 per cent effective against symptomatic COVID-19 infection in a large multinational study, and recently reported 76 per cent overall efficacy against symptomatic COVID-19 in another large study done primarily in the United States. THE CANADIAN PRESS/John Woods

AstraZeneca COVID-19 vaccine FAQ: Why do the age recommendations keep changing? Does it cause VIPIT blood clots? Is it effective against variants?

With changing recommendations about AstraZeneca's COVID-19 vaccine making headlines, many people have questions about its use.
A healthcare worker administers an Oxford/AstraZeneca COVID-19 vaccine to her colleague at Mutuini Hospital in Nairobi. Kenya on March 3, 2021. Photo by Dennis Sigwe/SOPA Images/LightRocket via Getty Images

Kenya’s COVID-19 vaccine rollout has got off to a slow start: the gaps, and how to fix them

Kenya grapples with two major challenges in the vaccination rollout: access to sufficient doses in light of the global shortage; and vaccine hesitancy.

Top contributors

More